The pathological hallmarks of Alzheimer’s disease (AD) include extracellular beta-amyloid plaques, neurofibrillary tangles, neuronal loss and tau deposits in brain. Therapies targeting these known hallmarks are yet to yield any meaningful benefit in clinical trials. We spoke to four researchers in the fields of AD research and therapy development to find out where they think the fields should head next.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders
Molecular Neurodegeneration Open Access 05 June 2020
-
Tacrine hybrids as multi-target-directed ligands in Alzheimer’s disease: influence of chemical structures on biological activities
Chemical Papers Open Access 14 September 2018
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stower, H. Searching for Alzheimer’s disease therapies. Nat Med 24, 894–897 (2018). https://doi.org/10.1038/s41591-018-0127-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-018-0127-2
This article is cited by
-
Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders
Molecular Neurodegeneration (2020)
-
Ultraviolet–visible–near-infrared optical properties of amyloid fibrils shed light on amyloidogenesis
Nature Photonics (2019)
-
Tacrine hybrids as multi-target-directed ligands in Alzheimer’s disease: influence of chemical structures on biological activities
Chemical Papers (2019)